{
  "pmcid": "10828925",
  "sha256": "2edd3a0f9c806dc74373c5783e34d9ced58fe0611df720dade5d84fadc289ff7",
  "timestamp_utc": "2025-11-09T21:57:27.750574+00:00",
  "model_used": "gpt-4o",
  "readability": {
    "flesch_kincaid": 11.165794016110475,
    "reading_ease": 34.1968843498274,
    "word_count": 237
  },
  "consort_scores": {
    "rubric_version": "v3.0-2025-10-14",
    "items": {
      "Title": {
        "score": 1,
        "evidence": "Randomised Controlled Trial of PLX-PAD in Chronic Limb-Threatening Ischaemia"
      },
      "Trial_Design": {
        "score": 2,
        "evidence": "multinational, parallel-group, placebo-controlled trial, 213 patients"
      },
      "Participants": {
        "score": 2,
        "evidence": "patients with CLTI and minor tissue loss"
      },
      "Intervention": {
        "score": 2,
        "evidence": "30 intramuscular injections into the index leg on days 0 and 60"
      },
      "Objective": {
        "score": 1,
        "evidence": "evaluated the efficacy of PLX-PAD, a placental-derived mesenchymal stromal cell-like therapy, in increasing amputation-free survival (AFS)"
      },
      "Method_Outcome": {
        "score": 2,
        "evidence": "The primary outcome was AFS, measured from randomisation to major amputation or death, over 12-36 months."
      },
      "Randomisation_Allocation": {
        "score": 2,
        "evidence": "Randomisation was conducted using permuted blocks, and allocation was concealed via an interactive web-based system."
      },
      "Blinding": {
        "score": 3,
        "evidence": "Patients, clinicians, and outcome assessors were blinded."
      },
      "Number_Randomised": {
        "score": 2,
        "evidence": "Between September 2017 and November 2020, 143 patients were randomised to PLX-PAD and 70 to placebo."
      },
      "Number_Analysed": {
        "score": 2,
        "evidence": "Analysis was conducted on 205 patients using an intention-to-treat approach."
      },
      "Result_Outcome": {
        "score": 3,
        "evidence": "HR 0.93, 95% CI 0.53 to 1.63; P = 0.788"
      },
      "Harms": {
        "score": 1,
        "evidence": "Adverse events were reported in 73.5% of PLX-PAD and 82.6% of placebo patients"
      },
      "Trial_Registration": {
        "score": 1,
        "evidence": "Trial registration: NCT03006770; EudraCT 2015-005532-18."
      },
      "Funding": {
        "score": 0,
        "evidence": "Funding: Not specified."
      }
    },
    "total_score": 24,
    "max_score": 25
  }
}